产品
编 号：F762629
分子式：C19H16ClFN2OS
分子量：374.86
分子式：C19H16ClFN2OS
分子量：374.86
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 2953044-29-4
产品详情
生物活性：
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research.
体内研究：
Animal Model:PD-L1+/? (H358 and ES2) tumor
Dosage:0.01-100 μM
Administration:incubation
Result:Observed 40-55% higher uptake in PD-L1+ H358 tumors than in wild-type counterparts.Failed to discriminate between wild-type and knock-out for ES2 slides.
体外研究：
PD-L1-IN-3 (Compound 4a) (0.01-100 μM, 40分钟) 破坏 PD-1 和 PD-L1 之间的结合，增强 TCR 介导的 Jurkat 细胞活化。PD-L1-IN-3 (0.01-100, 40分钟)在 PD-L1+ 在 H358 肿瘤中有较高的摄取，其摄取与 PD-L1 表达相关。
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research.
体内研究：
Animal Model:PD-L1+/? (H358 and ES2) tumor
Dosage:0.01-100 μM
Administration:incubation
Result:Observed 40-55% higher uptake in PD-L1+ H358 tumors than in wild-type counterparts.Failed to discriminate between wild-type and knock-out for ES2 slides.
体外研究：
PD-L1-IN-3 (Compound 4a) (0.01-100 μM, 40分钟) 破坏 PD-1 和 PD-L1 之间的结合，增强 TCR 介导的 Jurkat 细胞活化。PD-L1-IN-3 (0.01-100, 40分钟)在 PD-L1+ 在 H358 肿瘤中有较高的摄取，其摄取与 PD-L1 表达相关。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备